Marex Executive Plans $8.2M Stock Sale of Compensation Shares on Nasdaq

Marex Group has filed a Form 144 notice for the proposed sale of 210,000 shares of common stock through J.P.

Rhea-AI Filing Summary

Marex Group has filed a Form 144 notice for the proposed sale of 210,000 shares of common stock through J.P. Morgan Securities, with an aggregate market value of $8,219,400. The sale is scheduled for June 23, 2025, on the Nasdaq exchange.

The securities to be sold were acquired through multiple compensation grants:

• May 2024: 29,243 shares total
• March 2025: 105,122 shares total
• May 2025: 75,635 shares

The total shares outstanding are 71,231,706. The proposed sale represents approximately 0.29% of outstanding shares. No securities were reported sold by the filer during the past three months. This Form 144 filing indicates insider's intention to sell while affirming no knowledge of undisclosed material adverse information about the company.

Positive

• None.

Negative

• Insider plans to sell 210,000 shares worth $8.22M, representing approximately 0.29% of total outstanding shares

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares of MRX stock are being sold according to the Form 144 filing from June 2025?

According to the Form 144 filing, 210,000 shares of MRX common stock are proposed to be sold through J.P. Morgan Securities LLC, with an aggregate market value of $8,219,400.

What is the timing of the proposed MRX stock sale in the June 2025 Form 144?

The Form 144 indicates an approximate date of sale of June 23, 2025, with the filing made on June 28, 2025. The shares will be sold on the Nasdaq exchange through J.P. Morgan Securities LLC.

How did the seller acquire the MRX shares being sold?

The shares were acquired through multiple compensation grants from the issuer: 29,243 shares on May 24, 2024, 75,635 shares on May 16, 2025, and 105,122 shares on March 10, 2025, totaling 210,000 shares.

What percentage of MRX's outstanding shares does this Form 144 sale represent?

The proposed sale of 210,000 shares represents approximately 0.29% of MRX's total outstanding shares, as the filing indicates there are 71,231,706 shares outstanding.

Has the Form 144 seller made any other sales of MRX stock in the past 3 months?

According to the filing section 'Securities Sold During The Past 3 Months', there were no other sales reported by the seller during the past 3 months prior to this Form 144 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2025 - 04:08 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001379623
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Marex Group plc
SEC File Number	001-42020
Address of Issuer	155 Bishopsgate London UNITED KINGDOM EC2M 3TQ UNITED KINGDOM na
Phone	442076556000
Name of Person for Whose Account the Securities are To Be Sold	Ian Lowitt
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	CEO

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	J.P. Morgan Securities LLC 390 Madison Avenue 6th Floor New York NY 10017	210000	8219400	71231706	06/23/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/24/2024	Compensation	Issuer			24631	05/24/2024	NA
Common	05/24/2024	Compensation	Issuer			4612	05/24/2024	NA
Common	05/16/2025	Compensation	Issuer			75635	05/16/2025	NA
Common	03/10/2025	Compensation	Issuer			4612	03/10/2025	NA
Common	03/10/2025	Compensation	Issuer			100510	03/10/2025	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The sales of shares set forth herein are made in connection with a selling plan entered into on 14 March 2025 that is intended to comply with Rule 10b5-1
Date of Notice	06/23/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/14/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Ian Lowitt
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)